The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

Mads Ammitzbøll-Danielsen, Mikkel Østergaard, Esperanza Naredo, Annamaria Iagnocco, Ingrid Möller, Maria-Antonietta D'Agostino, Maria Antonietta D'Agostino, Frédérique Gandjbakhch, Lene Terslev

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)


Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.
Lingua originaleEnglish
pagine (da-a)165-169
Numero di pagine5
Stato di pubblicazionePubblicato - 2018


  • Adult
  • Aged
  • Arthritis, Rheumatoid
  • C-Reactive Protein
  • Female
  • Follow-Up Studies
  • Health Surveys
  • Humans
  • Male
  • Middle Aged
  • Omeract
  • Outpatients
  • Pain Measurement
  • Research Design
  • Rheumatoid arthritis
  • Statistics, Nonparametric
  • Synovitis
  • Tenosynovitis
  • Ultrasonography
  • Ultrasonography, Doppler


Entra nei temi di ricerca di 'The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials'. Insieme formano una fingerprint unica.

Cita questo